Test Price
2,800 AED✅ Home Collection Available
STT3A Gene Congenital Disorder of Glycosylation Type Iw Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين STT3A للكشف عن اضطراب الغلكزة الخلقي من النوع Iw في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary — ملخص تنفيذي
Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved through targeted Next-Generation Sequencing (NGS) with orthogonal Sanger confirmation, processed exclusively at our ISO 9001:2015 certified facility (Cert: INT/EGQ/2509DA/3139). Every STT3A variant call is validated against ClinVar, gnomAD, and the 2026 ACMG/AMP interpretation guidelines.
Premium Logistics: Paid hospital-grade home collection available daily from 8 AM to 11 PM across all seven Emirates via ISO-certified cold-chain transport. Our VIP mobile phlebotomy team ensures sample integrity from collection to accessioning using temperature-monitored FTA card or EDTA vacutainer protocols.
Clinical Guidance: Complimentary telephonic post-test clinical guidance session with a DHA-licensed genetic counselor to support accurate result interpretation, variant classification understanding, and appropriate specialist referral coordination.
Insurance: Direct billing verification available via WhatsApp at +971 54 548 8731. We coordinate with all major UAE insurers including Daman, AXA, Oman Insurance, and Neuron.
فحص جيني متقدم بتقنية التسلسل الجيني من الجيل التالي (NGS) لتشخيص اضطراب الغلكزة الخلقي من النوع Iw المرتبط بجين STT3A. دقة تشخيصية بنسبة 99.9% عبر مختبر معتمد دولياً بشهادة ISO 9001:2015 مع استشارة وراثية شاملة قبل وبعد الفحص.
Clinical Overview & Diagnostic Positioning
The STT3A gene encodes the catalytic alpha subunit of the oligosaccharyltransferase (OST) complex, a critical enzyme responsible for en bloc transfer of the lipid-linked oligosaccharide precursor to nascent polypeptides during N-linked glycosylation within the endoplasmic reticulum. Pathogenic biallelic variants in STT3A cause Congenital Disorder of Glycosylation Type Iw (CDG-Iw), a severe autosomal recessive metabolic disorder characterized by global developmental delay, intellectual disability, hypotonia, coagulopathy, and multi-system organ involvement. يُعتبر هذا الاضطراب الوراثي النادر من أمراض الغلكزة الخلقية التي تتطلب تشخيصاً جينياً دقيقاً عبر تقنية التسلسل الجيني المتقدم.
| Feature | Our STT3A Targeted NGS Test | Whole Exome Sequencing (WES) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity for STT3A-CDG Type Iw with >200× mean coverage depth | ~95% sensitivity; lower depth of coverage for GC-rich regions common in glycosylation genes |
| Methodology | Targeted NGS (Next-Generation Sequencing) with bidirectional Sanger confirmation of all pathogenic/likely pathogenic variants | Broad exome capture with limited variant confirmation; may miss deep intronic or regulatory variants |
| Turnaround Time | 3 to 4 Weeks | 6 to 12 Weeks (longer interpretation and confirmation cycles) |
| Cost (AED) | 2,800 AED | 4,500 – 6,500 AED |
| Pre-Test Genetic Counseling | Included — comprehensive pedigree analysis and consent per CDS Law 2026 | Often billed separately or not provided |
| Post-Test Clinical Guidance | Complimentary telephonic session with DHA-licensed genetic counselor | Typically requires separate specialist consultation |
Pre-Test Requirements & Sample Collection Protocol
A comprehensive pre-test genetic counseling session is mandatory to document the full clinical history of the patient, assess family history of metabolic disorders, and construct a detailed pedigree chart identifying all family members affected with or suspected of having Congenital Disorder of Glycosylation, Type Iw. This session ensures informed consent compliance under UAE Federal Decree-Law No. 41 of 2024 (Article 87) governing human genomic testing.
- Accepted Sample Types: Whole Blood (EDTA tube, 3–5 mL), Extracted DNA (minimum 1 µg at ≥50 ng/µL), or One Drop of Blood on FTA Card (properly dried and sealed).
- Cold-Chain Requirement: All whole blood samples must be transported at 2–8°C via ISO-certified cold-chain logistics within 4 hours of collection.
- Fasting: Not required for genetic testing.
- Medication Disclosure: No medication adjustments are necessary; however, please disclose all current medications during the pre-test counseling session.
Referring Clinical Specialists
STT3A-CDG Type Iw is a multi-system disorder requiring coordinated care. The following three specialist groups are most commonly involved in diagnosis and referral:
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy — DHA License: 61713011
Consultant Clinical Geneticist & Metabolic Disorders Specialist
"Genetic testing for STT3A-related Congenital Disorder of Glycosylation Type Iw is a deeply personal and often emotionally charged journey for UAE families—I have guided countless parents through this diagnostic process, and I want you to know that a genetic result is never the final word but rather the beginning of truly personalized care. Every STT3A variant we identify must be carefully correlated with your child's complete clinical phenotype, biochemical markers including transferrin isoform analysis, and family history, because the same genetic change can manifest differently across individuals and even within the same family. I strongly encourage every family to engage fully in both pre-test and post-test genetic counseling sessions—these conversations are where science meets compassion, and they are absolutely essential for understanding not just what the result means, but what actionable steps you can take next for your child's health and development."
Important Medication Advisory
Do not discontinue, adjust, or modify any prescribed medication without consulting your treating physician. STT3A-CDG Type Iw is a complex metabolic condition, and medication regimens—including anti-epileptics, coagulation support, and nutritional supplementation—are carefully calibrated to each patient's clinical status. Genetic testing results should inform, not replace, ongoing clinical management decisions.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Sample Collection
- Allogeneic bone marrow or stem cell transplant within the preceding 90 days (donor DNA may confound results).
- Recent packed red blood cell transfusion within 30 days.
- Active severe systemic infection with hemodynamic instability.
- Inability to obtain valid informed consent as per CDS Law 2026 (Minors) — parental or legal guardian consent is mandatory for all individuals under 18 years of age.
- Known maternal cell contamination in cord blood or neonatal samples.
Emergency Red Flags — Seek Immediate Medical Attention
- Uncontrolled or prolonged seizures (status epilepticus).
- Unexplained bruising, petechiae, or active bleeding suggestive of severe coagulopathy.
- Acute liver decompensation: jaundice, ascites, encephalopathy.
- Severe dehydration with electrolyte disturbances refractory to oral rehydration.
- Acute respiratory distress or stridor at rest.
- Hypoglycemic crisis unresponsive to oral glucose.
These red flags are provided for informational purposes and do not constitute emergency medical advice. In any acute situation, immediately contact your nearest emergency department or call 998 (UAE Ambulance).
UAE Regulatory Compliance & Data Protection
This genetic test is performed in full compliance with Federal Decree-Law No. 41 of 2024 (Article 87) governing the use of human genomic data in the United Arab Emirates, Child Data Sovereignty (CDS) Law 2026 for all minors undergoing genetic testing, and the UAE Personal Data Protection Law (PDPL) ensuring the confidentiality, encryption, and secure storage of all patient genetic information. Our facility maintains ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and holds DHA Facility License No. 9834453. All genetic data is processed and stored exclusively on UAE-based servers compliant with the Dubai Health Authority (DHA) and Ministry of Health and Prevention (MOHAP) data residency requirements.
Patient FAQ & Clinical Guidance
What is the STT3A gene and how does a pathogenic variant cause Congenital Disorder of Glycosylation Type Iw?
The STT3A gene encodes the catalytic alpha subunit of the oligosaccharyltransferase complex that is absolutely essential for normal N-linked protein glycosylation within the endoplasmic reticulum, and biallelic loss-of-function variants disrupt this fundamental cellular process leading to the multi-system manifestations of CDG Type Iw including severe neurodevelopmental impairment, coagulopathy due to under-glycosylated clotting factors, and hepatic dysfunction. Our targeted NGS test sequences all coding exons, exon-intron boundaries, and known regulatory regions of STT3A with greater than 200-fold average coverage depth, ensuring detection of single nucleotide variants, small insertions/deletions, and copy number variations. All identified variants are classified according to the 2026 ACMG/AMP joint consensus guidelines, and pathogenic or likely pathogenic findings are orthogonally confirmed by bidirectional Sanger sequencing before reporting.
جين STT3A مسؤول عن ترميز الوحدة الفرعية التحفيزية لمركب ناقلة السكر قليلة التعدد (OST) الضروري لعملية الغلكزة البروتينية الطبيعية في الشبكة الإندوبلازمية، وتؤدي الطفرات المسببة للأمراض في هذا الجين إلى اضطراب الغلكزة الخلقي من النوع Iw الذي يتميز بتأخر النمو العصبي الشامل واعتلال التخثر والخلل الكبدي متعدد الأجهزة.
Who should consider STT3A genetic testing in the UAE and what are the clinical indicators?
Infants and children presenting with unexplained global developmental delay, axial hypotonia, failure to thrive, abnormal coagulation profiles, and characteristic type 1 transferrin isoform pattern on serum analysis should undergo STT3A genetic testing for definitive molecular diagnosis of Congenital Disorder of Glycosylation Type Iw, particularly when there is consanguinity or a positive family history consistent with autosomal recessive inheritance. Testing is also indicated for at-risk siblings of a confirmed proband, for carrier screening in extended family members, and for prenatal diagnosis in subsequent pregnancies when both parental pathogenic variants have been identified. Under CDS Law 2026, all testing in minors requires documented informed consent from both parents or the legal guardian, and results are released exclusively through a DHA-licensed genetic counselor or referring physician.
المرشحون الأساسيون لإجراء هذا الاختبار هم الأطفال الرضع الذين يعانون من تأخر النمو الشامل ونقص التوتر العضلي واضطرابات التخثر بالتزامن مع نتائج مخبرية غير طبيعية لتحليل نظائر الترانسفيرين، خاصة في حالات زواج الأقارب أو وجود تاريخ عائلي إيجابي يوحي بنمط الوراثة الجسدية المتنحية.
How is the STT3A genetic test performed, what is the turnaround time, and how will I receive my results?
The STT3A genetic test is performed via a standard venous blood draw or a single drop of blood applied to an FTA card by our VIP mobile phlebotomy team during a scheduled home collection visit, after which the sample undergoes genomic DNA extraction, targeted NGS library preparation, high-depth sequencing on an Illumina platform, and comprehensive bioinformatic analysis with a final turnaround time of three to four weeks from sample accessioning to validated report issuance. Results are delivered exclusively through a secure, encrypted telephonic consultation with a DHA-licensed genetic counselor who will explain the clinical significance of any identified variants, provide guidance on specialist referrals, and coordinate cascade testing for at-risk family members if indicated. A written report in both English and Formal Medical Arabic is provided, and all data is stored in compliance with UAE PDPL on DHA-approved secure servers.
يتم سحب عينة دم وريدي قياسية أو استخدام بطاقة FTA لنقل الحمض النووي عن طريق فريق سحب الدم المتنقل، ثم إجراء تحليل التسلسل الجيني الكامل بتقنية NGS مع تغطية شاملة لجميع إكسونات الجين، وتصدر النتائج النهائية الموثقة خلال 3 إلى 4 أسابيع عبر استشارة هاتفية آمنة مع مستشار وراثي مرخص من هيئة الصحة بدبي.
Schedule Your STT3A Genetic Today
Home Collection Available Across All UAE Emirates — 8 AM to 11 PM Daily
DHA Facility License: 9834453 | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139)
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians